Effect of Bisphosphonates on Bone Health in Adult Renal Transplant Patients: Beyond the First Year Posttransplant

Abstract

French

Background:

Bone mineral density (BMD) decreases postrenal transplantation. Evidence demonstrating the effects of bisphosphonates on BMD and fracture risk beyond 1-year posttransplant is sparse in existing literature, but remains essential to enhance clinical outcomes in this population.

Objective:

Our study aimed to systematically review and meta-analyze the current literature on the use of any bisphosphonate in the adult renal transplant population beyond the first year of renal transplant to determine its effect on BMD and fracture incidence.

Design:

We conducted a systematic review and meta-analysis of primary research literature that included full-text, English-language, original randomized clinical trials (RCTs) and observational studies.

Setting:

Patient data were primarily captured in an outpatient setting across various studies.

Patients:

Our population of interest was patients older than 18 years who received deceased/living donor kidney transplantation and any bisphosphonate with a follow-up greater than 12 months posttransplantation.

Measurements:

The primary outcome was change in BMD from baseline. Secondary outcomes were the incidence of fractures and effects of other confounders on bone health.

Methods:

We included RCTs and observational studies that satisfied our inclusion criteria. Each study was analyzed for risk of bias and data were extrapolated to analyze for overall statistical significance accounting for heterogeneity of studies.

Results:

Sixteen studies (N = 1762) were analyzed. The follow-up ranged from 12 to 98 months. There was a nonsignificant improvement in BMD with bisphosphonate treatment persisting into the second and third years posttransplant at the lumbar spine. The calculated standardized mean BMD difference was −0.29 (−0.75 to 0.17), P = .22. Only 5 studies reported a total of 43 new fractures. Prednisone (P < .01), low body weight (P < .001), low body mass index (P < .01), and male gender (P < .05) correlated with reduced lumbar and femoral BMD.

Limitations:

Limitations of this review include the use of BMD as a surrogate outcome, the bias of the included studies, and the incomplete reporting data in numerous analyzed studies.

Conclusions:

We demonstrate no statistically significant benefit of bisphosphonate treatment on BMD beyond the first year postrenal transplantation. Despite heterogeneity of treatment, a differential nonsignificant improvement in lumbar spine BMD was consistent and may be clinically relevant.

Trial Registration:

PROSPERO CRD42019125593

Keywords

renal transplantation osteodystrophy bisphosphonate

What was known before

Rapid bone loss occurs in the first year postrenal transplantation but is a chronic disease. Existing systematic reviews identify a benefit of bisphosphonates in reducing bone mineral density (BMD) loss in the first 12 months posttransplant.

What this adds

This current review adds there is no statistically significant benefit to bisphosphonate treatment on BMD beyond 1 year postrenal transplantation.

Introduction

End-stage renal disease (ESRD) is associated with renal osteodystrophy (osteitis fibrosa, adynamic bone disease, and osteomalacia).^1-4 A well-functioning renal allograft ameliorates many metabolic abnormalities associated with the development of mineral and bone disorders (MBDs) of ESRD. However, renal transplant recipients are particularly susceptible to bone damage due to a multitude of factors including preexisting bone disorders, immunosuppression, and alteration in the renal-bone metabolism axis.^5,6

Bone mineral density (BMD) measured by dual-energy X-ray absorptiometry (DEXA) has been shown to decrease below 2 standard deviations (SDs) posttransplantation,⁷ with estimated 3%-7% loss in the lumbar spine in the first year.^8-11 Ongoing vertebral bone loss (approximately 2%/yr) has been demonstrated in longitudinal evaluation of BMD in 70 renal transplant recipients.¹²

There are few studies demonstrating that low BMD predicts fractures in renal recipients. Akaberi et al¹³ showed that low hip BMD predicted fractures in 238 renal recipients. The prevalence of fractures in the posttransplant population is up to 4-fold greater than pretransplant statistics, ranging widely between 5% and 44%, likely due to variations in observation time, definitions of fractures included, and the presence of diabetes.^14-17

There is currently no established strategy for the prevention of posttransplant osteopenia and osteoporosis. Bisphosphonates, which inhibit osteoclast activity, are widely accepted as a treatment for osteopenia and osteoporosis in the general population.¹⁸ They have also been shown to protect against bone loss in the renal transplant recipients,^1,7,19,20 although a specific risk is the potential to exacerbate a baseline low-turnover adynamic state.^1,21,22

The currently available research on bisphosphonate use in the renal transplant population is limited to analysis of randomized clinical trial (RCTs) within the first year posttransplant^18,23-25 The first year posttransplant is wrought with confounding factors including the physiologic adjustments in metabolism, the uremic effects of ESRD, the fluctuant nature of the posttransplant course, and aggressive immunosuppression.

Methods

Eligibility Criteria

We conducted a systematic review and meta-analysis of primary research literature that included full-text, English-language, original RCTs and observational studies. Our population of interest was patients older than 18 years who received deceased/living donor kidney transplantation and any bisphosphonate with a follow-up greater than 12 months posttransplantation (Figure 1). Supplemental Table S1 summarizes the inclusion and exclusion criteria of our review.

Figure 1.

Summary of study timelines in postrenal transplant patients on bisphosphonate therapy.

Search Strategy

Electronic searches were performed in MEDLINE, EMBASE, and the Cochrane Register of Controlled Trials (CENTRAL) between 1946 and 2017 (Figure 2). A sample search strategy is outlined in Supplemental Figure 1.

Figure 2.

Schema of literature search.

Data Extraction and Outcome Measures

Each included study was assessed in conjunction by 2 authors (A.L. and A.W.) for data extraction (Tables 1 -4). The primary outcome was the change in BMD from baseline. The secondary outcomes were the incidence of fractures and the effects of other confounders that may modify the risk of osteoporosis and fractures.

Table 1.

Duration of Bisphosphonate Therapy and Follow-up in Postrenal Transplant Patients.

Study	Treatment	Concomitant treatment	Treatment start date	Treatment duration	Time of outcome analysis from treatment initiation
Sánchez-Escuredo et al²⁶	Oral ibandronate 150 mg monthly (n = 35) Control: Oral risedronate 35 mg weekly (n = 34)	CaCO₃ 2500 mg Vitamin D 800 IU	At least 12 months posttransplant	12 months	12 months
Okamoto et al²⁷	Oral alendronate 35 mg per week (n = 5) Control: no bisphosphonates (n = 7)	Not specified	At least 12 months posttransplant	24 months	24 months
Walsh et al²⁸	IV pamidronate 1 mg/kg within 14 days of transplant and 1, 4, 8, and 12 months after transplant (n = 46) Control: no intervention (n = 47)	Calcium CaCO₃ 500 mg Cholecalciferol 400 IU	At transplantation	12 months	3, 6, 12, and 24 months
Lan et al²⁹	Alendronate 70 mg/wk for 6 months (n = 23) Control: no intervention (n = 23)	CaCO₃ 800 mg Calcitriol 0.25 µg for 6 months	Treatment: 25.9 ± 10.6 months Control: 27.1 ± 12.4 months	6 months	6 months
Schwarz et al³⁰	IV zoledronic acid 4 mg at 2 weeks and 3 months (n = 9) Control: placebo (n = 10)	Calcium citrate 1000 mg daily for first 6 months	At time of transplantation	2 doses—at 2 weeks and 3 months posttransplant	6 to 36 months
Fan et al³¹	IV pamidronate 0.5 mg/kg at the time of transplant and 1 month later (n = 9) Control: 500 mL NS (n = 8)	Not specified	At the time of transplantation	2 doses—at the time of transplant and 1 month later	12 and 48 months
Jeffery et al³²	Alendronate 10 mg/d open label (n = 57; 46 completed 1 year) Control: Calcitriol 0.25 µg/d (n = 60; 51 completed 1 year)	Calcium 500 mg/d	102 ± 80.4 months (8.5 ± 6.7 years) posttransplantation	12 months	12 months
Koc et al³³	1: Alendronate 10 mg/d (n = 8) 2: Calcitriol 0.5 µg/d (n = 8) Control: no intervention (n = 8)	Calcium 1000 mg/d	Minimum duration of renal transplant was 12 months	Study period: 12 months	12 months
Tillmann et al³⁴	IV ibandronate 3 mg every 3 months (average dose 12.0 ± 6.7 g) (n = 30) Control: No intervention (n = 30)	Not specified	51.0 ± 61.4 months after transplant First BMD measured at minimum 14 months posttransplant	Average 19.3 ± 11 months	26.8 ± 12.1 months after first measurement
Naylor et al³⁵	Unspecified bisphosphonate, grouped into “osteoporosis treatment”—includes >90% bisphosphonate, nasal calcitonin, raloxifene, systemic estrogen (n = 329) No comparator	—	—	—	Mean 98.4 months (8.2 years) follow-up from study start
Yamamoto et al³⁶	Oral alendronate 35 mg/wk (n = 24) No control group	Not specified	129.6 ± 40.8 months (10.8 ± 3.4 years) posttransplant	36 months treatment period	12 and 24 months
Huang et al³⁷	Alendronate 70 mg/wk (n = 41) Control: no intervention (n = 35)	Not specified	At least 5 months posttransplantation	Duration of treatment unclear	14 ± 1.6 months
Conley et al³⁸	Bisphosphonate as prescribed by treating physician (n = 315) Control: no intervention (n = 239)	Intervention: Calcium = 170 (71.1%) Vitamin D = 35 (14.6%) Active vitamin D = 11 (4.6%) Control: Calcium = 220 (69.8%) Vitamin D = 83 (26.3%) Active vitamin D = 39 (12.4%)	12 months posttransplant	Treatment duration not specified	Not consistent
Ahn et al³⁹	Oral alendronate sodium or risedronate sodium (dose not specified) Control: alfacalcidol (dose not specified) (n = 294, total)	Calcium (dose not specified)	In study group, within 1 month of transplant	Treatment duration not specified	12, 24, and 36 months posttransplant
Cruz et al⁴⁰	Oral alendronate 10 mg/d (n = 29, high risk) Control: no intervention (n = 28, low risk)	None	12 months posttransplant	Study period: 12 months	12 months
Arlen et al⁴¹	Oral etidronate disodium 400 mg for 2 weeks of every 12 weeks (n = 25) Control: no intervention (n = 24)	Calcium replacement and Vitamin D at the discretion of the treating physicians Patients held medication during the 2 weeks of treatment Intervention: CaCO₃ (n = 3) Calcitriol (n = 4) Control: CaCO₃ (n = 3) Calcitriol (n = 8)	Treatment: 10.4 ± 5.3 months after transplant Control: 10.7 ± 4.5 months	Study period: 12 months	12 months

Note. IU = international unit; IV = intravenous; NS = normal saline; BMD = bone mineral density. White is RCT, Grey shaded region is Observational trials.

Table 2.

Baseline Characteristics of Included Studies.

Study	Year	Population (male/female)	Mean age (mean ± SD)	Time after transplant	Intervention	Comparator	Funding support
Randomized control trials
Sánchez-Escuredo et al	2015	77 (19/58)	Ibandronate: 63 ± 12 Risedronate: 64 ± 10	Ibandronate: 20 ± 8 months Risedronate: 18 ± 7 months	Ibandronate 150 mg/month Vitamin D 800 IU CaCO₃ 2500 mg (n = 38)	Risedronate 35 mg/wk Vitamin D 800 IU CaCO₃ 2500 mg (n = 39)	NA
Okamoto et al	2014	12 (8/4)	Alendronate: 52.8 ± 12.6 Control: 52.9 ± 7.3	Alendronate: 59.6 ± 59.5 months Control: 45.3 ± 42.3 months	Alendronate 35 mg/wk for 24 months (n = 5)	No intervention (n = 7)	MSD K.K.
Walsh et al	2009	93 (69/24)	Treatment: 46.1 ± 12.77 Control: 46.1 ± 12.93	0	Pamidronate IV 1 mg/kg peri-op, 1, 4, 8 and 12 months CaCO₃ 500 mg Cholecalciferol 400 units (n = 46)	CaCO₃ 500 mg Cholecalciferol 400 units (n = 47)	Novartis
Lan et al	2008	46 (19/27)	Treatment: 40.2 ± 18.5 Control: 39.4 ± 17.3	Treatment: 25.9 ± 10.6 months Control: 27.1 ± 12.4 months	Alendronate 70 mg/wk CaCO₃ 800 mg/d Calcitriol 0.25 µg/d (n = 23)	CaCO₃ 800 mg/d Calcitriol 0.25 µg/d (n = 23)	Not reported
Schwartz et al	2004	19 (not reported)	Not reported	0	Two infusions of 4 mg zoledronic acid at 2 weeks and 3 months posttransplant (n = 9)	Placebo (n = 10)	Not reported
Fan et al	2003	I26 (26/0)	Treatment: 46.2 (21.1-67.1) Control: 41.5 (21.3-65) Mean age calculated with only patients with BMD measurements at 4 years	Not reported	Pamidronate IV 0.5 mg/kg in 500 mL NS peri-op and at 1 month (n = 14)	500 mL NS (n = 12)	Not reported
Jeffrey et al	2003	117 (97 completed treatment) (71/26)	Treatment: 44.8 ± 11.6 Control: 45.9 ± 10.8 Mean age documented is at the time of transplant and calculated with only patients who completed treatment	Treatment: 85.2 ± 62.4 months Control: 115.2 ± 81.6 months Mean duration calculated with only patients who completed treatment	Alendronate 10 mg/d open label Calcium (unspecified dose) (n = 60) 46 completed treatment	Calcitriol 0.25 µg/d Calcium (unspecified dose) (n = 57) 51 completed treatment	Not reported
Koc et al	2002	24 (17/7)	Alendronate: 34.3 ± 8.9 Calcitriol: 40.5 ± 8.1 Control: 35.5 ± 8.4	Alendronate: 48.7 ± 50.1 months Calcitriol: 47.4 ± 46.4 months Control: 41.5 ± 37.1 months	I1: Alendronate 10 mg/d Calcium 1000 mg/d (n = 8) I2: Calcitriol 0.5 µg/d Calcium 1000 mg/d (n = 8)	Calcium 1000 mg/d (n = 8)	Not reported
Observational studies
Naylor et al	2014	326 (199/27)	46.1 ± 12	6.12 (2.4-24) months	>90% bisphosphonates, nasal calcitonin, raloxifene, systemic estrogen	No control group	NA
Yamamoto et al	2013	24 (12/12)	52 ± 7.8	129.6 ± 40.8 months	Alendronate 35 mg/d	No control group	NA
Huang et al	2012	76 (36/40)	Treatment: Male: −51.9 ± 9.0 Female: −53.3 ± 8.8 Control: Male: −48 ± 10.4 Female: −49.7 ± 7.6	Treatment: Male: −103.7 ± 59.4 Female: −53.3 ± 8.8 Control: Male: −92 ± 68.1 Female: −61.4 ± 39.6	Alendronate 70 mg/wk (n = 34)	No intervention (n = 42)	NA
Conley et al	2008	554 (320/234)	Treatment: 45.9 ± 0.7 Control: 46.9 ± 0.2	Not reported	Bisphosphonate, type not described Calcium = 170 (71.1), Vitamin D = 35 (14.6), Active vitamin D = 11 (4.6) (n = 315)	Calcium = 220 (69.8) (NS) Vitamin D = 83 (26.3) (P = .001) Active vitamin D = 39 (12.4) (P = .003) (n = 239)	Not reported
Ahn et al	2006	294	Not reported	Within 1 month	Calcium Alfacalcidol or bisphosphonate (alendronate or risendronate)	No intervention	Not reported
Cruz et al	2002	58 (39/19)	Treatment: 48.6 ± 2.0 Control: 46.2 ± 2.0	Treatment: 97.2 ± 8.4 months Control: 84 ± 10.8 months	Alendronate 10 mg/d (n = 29)	No intervention (n = 29)	NCRR grant, National Kidney Foundation of Connecticut, NIH
Arlen et al	2001	49 (29/20)	Treatment: 41 ± 13 Control: 42 ± 12	Treatment: 10.4 ± 5.2 months Control: 10.8 ± 4.5 months	Etidronate disodium 400 mg for 2 weeks out of every 12 CaCO₃ (n = 3) Calcitriol (n = 4) (n = 25)	No intervention CaCO₃ (n = 3) Calcitriol (n = 8, P < .03) (n = 24)	Not reported
Tillmann et al	2001	60 (24/36)	Treatment: 47.9 ± 13.4 Control: 45.7 ± 11.4 Mean age documented is at the time of transplant	Treatment: 51 ± 61.4 months Control 59.6 ± 59.7 months	Ibandronate 3 mg IV Q3 months (n = 30)	No intervention (n = 30)	None

Note. IU = international unit; NA = not applicable; IV = intravenous; BMD = bone mineral density; NS = normal saline; NCRR = National Center for Research Resources; NIH = National Institutes of Health.

Table 3.

Change in Bone Mineral Density in Postrenal Transplant Patients Between Bisphosphonate and Control Groups.

Study	BMD
Study	Lumbar	Femoral neck	Other
Sánchez-Escuredo et al²⁶ I1: n = 35 I2: n = 34	T-score at pretreatment/12 months I1: −1.7 ± 0.8/−1.4 ± 0.6 I2 −1.9 ± 0.8/−1.5 ± 0.8	T-score at pretreatment/12 months I1: −2.1 ± 0.7/−1.8 ± 0.9 I2: −2.2 ± 0.6/−1.8 ± 0.8
Okamoto et al²⁷ I: n = 5C: n = 7	NA	NA	Total BMD:% change from baselineI: 1.86% ± 0.85%, P < .05No other raw data provided
Walsh et al²⁸ I: n = 46C: n = 47	% change in BMD at 12 months from baselineAMTD: 7.78%, 95% CI: 5.15-10.41, P < .001Significant difference between groups at 24 monthsNo raw data	% change in BMD at 12 months from baselineAMTD: 2.51%, 95% CI: −0.33 to 5.35, P = .08No significant difference between groups at 24 monthsNo raw data	Ward’s area:Significant increase in I vs C at both 12 and 24 monthsAMTD: 5.83%, 95% CI: 2.19-9.45, P < .01Total hip:Significant increase in I vs C at both 12 and 24 monthsAMTD: 2.79%, 95% CI: 0.92-4.67, P < .01
Lan et al²⁹ I: n = 23C: n = 23	Mean g/cm² at pretreatment/6 monthsI: (L1) 0.781 ± 0.117/0.820 ± 0.114, NSC: (L1) 0.760 ± 0.062/0.771 ± 0.069, NS	Mean g/cm² at pretreatment/6 monthsI: 0.650 ± 0.107/0.731 ± 0.109, P < .05C: 0.657 ± 0.061/0.676 ± 0.060, NSSignificant difference between groups at 6 months posttreatment,P < .05	Trochanter:Mean g/cm² at pretreatment/6 monthsI: 0.524 ± 0.093/ 0.572 ± 0.103, NSC: 0.54 ± 0.082/ 0.561 ± 0.079, NS
Schwarz et al³⁰ I: n = 9C: n = 10	Z-score at 6 months to 32 months posttreatmentI: No differenceC: No differenceNS between groupsNo raw data	Z-score at 6 months to 32 months posttreatmentI: −1.6 (2.9) to −1.2 (1.9), P < .05between groups, P < .05C: −1.3 (2.6) to −0.2 (3.6), P < .05between groups, P < .05median and range
Fan et al³¹ I: n = 9C: n = 8	Mean g/cm² at baseline/1 year/4 yearsI: 1.15 ± 0.07/(1 year) 1.11 ± 0.05, NS/(4 years) 1.10 ± 0.04, NSC: 1.27 ± 0.07/(1 year) 1.2 ± 0.5, P < .05/(4 years) 1.21 ± 0.08, NS	Mean g/cm² at baseline/1 year/4 yearsI: 0.93 ± 0.05/(1 year) 0.94 ± 0.04, NS/(4 years) 0.88 ± 0.04, NSC: 1.08 ± 0.07/ (1 year) 0.98 ± 0.06, P < .05/(4 years) 0.94 ± 0.06, P < .01
Jeffery et al³² I: n = 57C: n = 60	Mean g/cm² at pretreatment/12 monthsI: 0.984 ± 0.149/1.025 ± 0.143, P < .001C: 1.014 ± 0.15/1.034 ± 0.146, P < .01NS between groups at 12 months (P = .082)	Mean g/cm² at pretreatment/12 monthsI: 0.809 ± 0.092/0.836 ± 0.107, P < .001C: 0.830 ± 0.144/0.857 ± 0.125, P < .05NS between groups at 12 months (P = .96)
Koc et al³³ I1: n = 8I2: n = 8C: n = 8	Mean g/cm² at 12 months/pretreatmentI1: 1.050 ± 0.086/1.122 ± 0.094, P < .01I2: 0.963 ± 0.142/ 1.034 ± 0.119, P < .05C: 1.082 ± 0.187/1.095 ± 0.142, NS% change of BMDI1: 8.15% ± 9.2%I2: 6.89% ± 4.03%C: 0.06% ± 1.41%P < .05 compared with control	Mean g/cm² at 12 months/pretreatmentI1: 0.826 ± 0.121/ 0.902 ± 0.092, P < .05I2: 0.816 ± 0.121/0.902 ± 0.092, NSC: 0.933 ± 0.082/0.947 ± 0.082, NS% change of BMDI1: 9.34 ± 10.47%I2: 8.51 ± 13.8%C: 1.92 ± 2.52%NS compared with control
Tillmann et al³⁴ I: n = 30C: n = 30	Z-score at pre-treatment/26.8 ± 12.1 monthsI: −2.25 ± 1.11/−1.78 ± 1.30, P < .05C: −0.52 ± 1.52/−0.28 ± 1.55, P < .05Change in BMDI: 0.055 ± 0.066C: 0.033 ± 0.079NS between groups, P = .217	Z-score at pretreatment/26.8 ± 12.1 monthsI: −1.97 ± 0.85/−1.73 ± 0.71, P < .05C: −0.69 ± 1.31/−0.55 ± 1.12, P < .05Change in BMDI: 0.025 ± 0.077C: 0.013 ± 0.106NS between groups, P = .647
Naylor et al³⁵ n = 329	Z-score−0.4 ± 1.6At median 6 months (baseline)−0.2 ± 1.6, P < .001 vs baselineAt mean 2.7 years+0.5 ± 1.5, P < .001 vs baselineAt mean 8.2 years	Z-score−0.7 ± 1.1At median 6 months (baseline)−0.6 ± 1, P < .01 vs baselineAt mean 2.7 years+0.1 ± 1.5, P < .001 vs baselineAt mean 8.2 years	Hip Z-score−0.7 ± 1.1At median 6 months (baseline)−0.6 ± 1.1, P < .01 vs baselineAt mean 2.7 years−0.5 ± 1.1, P < .001 vs baselineAt mean 8.2 years
Yamamoto et al³⁶ n = 24	Mean g/cm² pretreatment/12 months/24 months(Baseline) 0.80 ± 0.11/(12-month) 0.78 ± 0.12, NS/(24-month) 0.79 ± 0.15, NS
Huang et al³⁷ I: n = 34C: n = 42	For 76 included patientsT-score at pretreatment/14 ± 1.6 months−1.53 ± 1.24/−1.32 ± 1.26, P < .001BMD: Mean g/cm² at pretreatment/14 ± 1.6 months0.90 ± 0.14/0.92 ± 0.14, P = .001	T-score at pretreatment/14 ± 1.6 months−2.45 ± 0.96/−2.42 ± 1.02, NSBMD: Mean g/cm² at pretreatment/14 ± 1.6 months0.68 ± 0.12/ 0.69 ± 0.13, NS	Hip:T-score at pretreatment/14 ± 1.6 months−1.76 ± 0.97/−1.68 ± 1.07, NSBMD: Mean g/cm² at pretreatment/14 ± 1.6 months0.81 ± 0.14/0.81 ± 0.14, NS
Conley et al³⁸ I: n = 315C: n = 239	T-score at mean 1.2 ± 0.05 years posttransplant/2.5 ± 0.05 years posttransplantI: −1.4 ± 1.3/−1.0 ± 1.3C: 1.3 ± 0.5/0 ± 1.4P < .001 between groups	T-score at mean 1.2 ± 0.05 years posttransplant/2.5 ± 0.05 years posttransplantI: −1.9 ± 1/−1.7 ± 1C: 1.0 ± 0/−1.0 ± 1.0P < .001 between groups
Ahn et al³⁹ n = 294	Mean different in T-score at 12, 24, and 36 months compared with baseline1 year C/I:−0.51 ± 0.66/−0.13 ± 0.73, P < .05 (n = 275/19)2 year C/I:−0.76 ± 0.74/−0.4 ± 0.79, P < .05 (n = 151/45)3 year C/I:−0.83 ± 0.83/−0.5 ± 0.8, P = .10 (n = 74/32)	Mean different in T-score at 12, 24 and 36 months compared with baseline1 year C/I:−0.22 ± 0.69/0.13 ± 0.55, P < .05 (n = 273/19)2 year C/I:−0.38 ± 0.82/−0.1 ± 0.77, P = .20 (n = 150/44)3 year C/I:−0.43 ± 0.85/0.20 ± 0.94, P = .21 (n = 75/31)
Cruz et al⁴⁰ I: n = 29C: n = 28	T-score at pretreatment/12 monthsI: −1.71 ± 0.19/no raw data result(change in T-score: + 3.4% ± 0.6%, P < .001)C: −0.70 ± 0.24/no raw data result	T-score at pretreatment/12 monthsI: −1.43 ± 0.13/−1.34 ± 0.14(P < .01) (change in T-score +1.6 ± 0.6%, P < .001)C: −1.10 ± 0.15/no raw data result	Total femur:T-score at pretreatment/12 monthsI: −1.43 ± 0.13/−1.34 ± 0.14 (P < .01) (change in T-score: +1.6 ± 0.6%, P < .001)C: −0.67 ± 0.16/no raw data result
Arlen et al⁴¹ I: n = 25C: n = 24	Mean g/cm² at pretreatment/23.3 ± 6.6 monthsI: 0.981 ± 0.138/1.021 ± 0.140C: 1.134 ± 0.168/1.143 ± 0.175Change in % BMD (I vs C)4.3% ± 6.1% vs 0.55 ± 5.3%, P < .05	Mean g/cm² at pretreatment/23.3 ± 6.6 months (change in % BMD)I: 0.784 ± 0.102/ 0.810 ± 0.110C: 0.867 ± 0.137/ 0.893 ± 0.147Change in % BMD (I vs C)3.4 ± 6.5% vs 3.2 ± 6.4% NS	Trochanter:Mean g/cm² at pretreatment/23.3 ± 6.6 months (change in % BMD)I: 0.619 ± 0.094/0.683 ± 0.126C: 0.725 ± 0.116/ 0.738 ± 0.109Change in % BMD (I vs C)10.3 ± 11.9% vs 2.2 ± 5.7%, P < .05

Note. BMD = bone mineral density; I = intervention; C = control; n = number; AMTD = adjusted mean treatment difference; CI = confidence interval. White is RCT, Grey shaded region is Observational trials.

Table 4.

Fracture Incidence in Postrenal Transplant Patients Between Bisphosphonate and Control Groups.

Study	Protocol	Baseline fractures	New fracture incidence			Findings
Walsh et al²⁸	Spine radiographs at baseline, 12, 24 monthsBlinded interpretation using Genant et al⁴² scale	N = 23/93 total12/46 in intervention group (1 axial)11/47 in control group		At 12 months	At 24 months	4.2% (−7.3 to 16.6) difference between groups at 12 months (P = .7)8.4% (−3.7 to 22.2) between groups at 24 months (P = .3)
			I (n = 46):	2	2(3.3%/yr)
			C (n = 47):	4	6(6.4%/yr)
Schwarz et al³⁰	Not formally assessed as endpoint	Not assessed	Between 6 months and 3 years:I (n = 9): 2 vertebral fracturesC (n = 10): 2 vertebral fractures			No analysis done
Yamamoto et al³⁶	Nontraumatic (low energy) fracturesAssessed via personal interviews and medical records	N = 7/24(4 wrist, 2 rib, 1 leg, 1 cuboidal)	4 patients with 5 fractures during 3-year period(2 leg, 1 lumbar spine, 1 hip, 1 humeral)			New fractures correlated with higher intact PTH levels (pg/mL) at baseline:Fracture (−) = 116.0 ± 52.6Fracture (−) = 255.0 ± 3.0 (P < .0001)
Conley et al³⁸	Self-reportedCounted if occurring between BMD1 and BMD2 (both occurring >1 year posttransplant)	I: 56/315C: 16/239Significantly more patients with fracture in intervention group (P = .0002)	I: 16C: 7(P < .05)Increase in bone density between BMD1 and BMD2 did not prevent late fractures			Treatment associated with decreased probability of fracture-free survival (HR = 0.40; 95% CI = 0.29-0.73, P = .001)No association found between rate of bone loss and fractures, regardless of the bisphosphonate therapy
Arlen et al⁴¹	Not formally assessed as endpoint	Not assessed	I (n = 25): n = 2C (n = 24): n = 1			All patients who sustained fractures were from high-risk treatment group (BMD lower than mean baseline of control group)

Note. I = intervention; C = control; BMD = bone mineral density; PTH = parathyroid hormone; HR = hazard ratio; CI = confidence interval. White is RCT, Grey shaded region is Observational trials.

Bias Assessment

Articles were independently assessed by each reviewer (A.L. and A.W.), and dichotomized to low/high risk of bias based on standardized scoring systems. An RCT was considered low risk if it satisfied a score of 8 or more based on the Cochrane Risk of Bias Tool Criteria (Supplemental Table S2).⁴³ An observational trial was considered low risk if it satisfied a score of 3 or more based on the Newcastle-Ottawa Criteria (Supplemental Table S3).⁴⁴

Statistical Analysis

A standardized mean difference (SMD) and its 95% confidence interval (CI) were calculated to account for heterogeneity of different units of pre- and posttransplant measurements.⁴⁵ Using the 95% CIs, the SDs were then derived.⁴⁶ Subsequently, forest/funnel plots were created using the Cochrane Collaboration RevMan v5.3 software.⁴⁶ A random effects model was used to account for clinical heterogeneity of the meta-analyzed studies. Values of I² >50% and P < .10 were considered to indicate significant heterogeneity.

Results

Description of the Search

The search strategy yielded 1084 articles between 1946 and 2017. All titles and abstracts were reviewed independently by 2 authors (A.L. and A.W.) in accordance with inclusion criteria (Figure 2). Thirty-five articles were fully reviewed. Fourteen articles were differentially categorized between reviewers. These were independently reviewed and resolved by a third author (D.T.W.) to ascertain eligibility.

Description of Studies

Sixteen studies met full inclusion criteria (Table 1), including 8 randomized trials^26-33 and 8 observational studies.^34-41 Two RCTs^28,30 and 7 observational studies,^34-36,38-41 were considered to have low risk of bias (Supplemental Figures S2 and S3).

The total sample size was 1762 patients; 683 patients were treated with bisphosphonates while the remaining were allocated to various comparison groups. Bisphosphonates used included alendronate, alendronate/risedronate, pamidronate, zolendronate, ibandronate, and etidronate. Comparators included no therapy, calcium and/or vitamin D, calcitriol, placebo, an alternative bisphosphonate, and no control group. Baseline characteristic data of each study are summarized in Table 2.

From the RCTs, 226 patients were prescribed a bisphosphonate with a concomitant treatment with Ca and/or vitamin D in 212 patients. Bisphosphonate-treatment duration ranged from 1 to 24 months, with a follow-up duration of 12 to 24 months (Table 1). From the observational studies, 457 patients were prescribed a bisphosphonate. Of these patients, 223 had a concomitant treatment with Ca and/or vitamin D. Precise treatment was not clearly specified in an additional 624 patients. The range for bisphosphonate treatment was 12 to 36 months with a follow-up duration of 12 to 98.4 months (Table 1).

BMD measurement was performed using DEXA in all studies, with results most often expressed as T-scores representing the number of SDs that the measurement falls from the mean of a young population. A T-score of −1 to −2.5 describes osteopenia and less than −2.5 is diagnostic of osteoporosis.⁴⁷ Results were also reported as bone mineral content or Z-scores that describe the number of SDs from the mean value of gender and age-matched adults (Z-score less than or equal to −2 suggests abnormal bone loss).

Change in BMD

One year posttransplant

Thirteen studies demonstrated at least one site of improvement in BMD, while the other 3 studies^30,32,36 showed nonsignificant changes. However, only 2 studies^28,39 were able to capture patient data from the immediate peri-transplant period. At 12 months posttransplant, Walsh et al²⁸ identified a significant change in BMD in the intervention group vs control group, at the lumbar spine, +2.3% vs −5.7%, adjusted mean treatment difference (AMTD) 7.78%, P < .001. T-scores were also significantly different in the intervention vs control group at both the lumbar spine (−0.13 ± 0.73 vs −0.51 ± 0.66, P < .05) and the femoral neck (0.13 ± 0.55 vs −0.22 ± 0.69, P < .05) at 12 months.³⁹ Both intervention groups showed significant improvement with bisphosphonate persisting into the second^28,39 and the third year³⁹ posttransplantation at the lumbar spine, with no significant difference at the femoral neck (Table 3).

One year postinitiation of bisphosphonate

Thirteen studies captured BMD data at least 12 months postinitiation of bisphosphonate treatment. Only 2 of these studies did not exhibit a significant increase in BMD³² or Z-score³⁰ in the intervention vs control group in the lumbar spine at 12 and 32 months posttreatment.³²

Unlike the lumbar spine, all studies showed minimal change in BMD measurements at the femoral neck except for 3 studies^31,33,39 that showed a significant change (Table 3). Result interpretation of the significantly different Z-scores between groups posttreatment was inconclusive in the study by Tillmann et al³⁴ as pretreatment measurements were also different. Cruz et al⁴⁰ also found different T-scores at the femoral neck posttreatment (change in T-score +1.6% ± 0.6%, P < .001), but did not provide raw data of the control group to allow for comparison.

Using the calculated SMD between the intervention (bisphosphonate) and control groups, Figures 3 and 4 summarize the study findings that include pre and postbisphosphonate treatment information on BMD, at the lumbar spine and femoral neck, respectively. Data from 4 RCTs^29,31-33 and 3 observational studies^34,38,41 were included in analysis. There is a nonsignificant improvement in BMD favoring the use of bisphosphonates, as evidenced at both the lumbar spine and femoral neck. There was no statistical heterogeneity noted when a random effects model was used. The funnel plot demonstrates reasonable dispersion (Supplemental Figure S4).

Figure 3.

Change in bone mineral density at the lumbar spine in postrenal transplant patients between bisphosphonate and control groups.

Figure 4.

Change in bone mineral density at the femoral neck in postrenal transplant patients between bisphosphonate and control groups.

Fracture Incidence

Fracture incidence was low but only reported in 5 studies^{28,30,36,38,41} with a total of 43 new fractures. Conley et al³⁸ reported benefit from bisphosphate treatment and decreased fracture rates (hazard ratio [HR] = 6.7, 95% CI = 6-6284, P < .01), despite only a small subset of patients (n = 3) with baseline osteoporosis at the femoral neck. Conley et al³⁸ noted that bisphosphonate treatment was associated with decreased probability of fracture-free survival (HR = 0.40, 95% CI = 0.29-0.73, P = .001) in the initial analysis, even though treatment was associated with significant reduction in bone loss at the femoral neck (HR = 1.56, 95% CI = 1.21-2.06, P < .001) and lumbar spine (HR = 1.48, 95% CI = 1.13-1.98, P < .01). However, after adjusted analysis, no association was identified between bone loss and fractures regardless of the bisphosphonate treatment.³⁸

Confounding Factors Affecting BMD

Immunosuppression

Four studies^32,35,37,39 examined the effects of steroids on bone health. At baseline, patients with osteoporosis received a greater cumulative steroid dose than patients with osteopenia (1326.5 mg vs 724.5 mg; P < .01).³⁷ In a univariate analysis, prednisolone use was associated with osteoporosis (odds ratio [OR] = 5.18; 95% CI = 1.6-16.4, P < .01).³⁷ Jeffery et al³² described prednisone as an independent predictor of low BMD (multivariate, P < .01). Alternatively, Naylor et al³⁵ found greater glucocorticoid exposure was not associated with a significant change in BMD at the lumbar spine, total hip, and femoral neck (P > .05), regardless of whether the patient had received osteoporosis treatment before. Similarly, no BMD differences were observed, 1 year posttransplant, in recipients receiving steroids.³⁹ The effects of cyclosporine on BMD were examined in 2 studies^37,39 and demonstrated no effects up to 1 year posttransplant.

Body mass index

Three studies^32,35,39 found that low body weight (P < .001) and body mass index (BMI) (P < .01) were correlated with reduced lumbar and femoral BMD in a univariate analysis.³² Greater BMI was associated with a better BMD.^35,39

Gender

Five studies^{32,34,35,37,39} examined the role of gender in BMD posttransplantation. Only one study³² identified a baseline association between female gender and reduced lumbar and overall BMD (P < .05). The other studies found no significant difference in gender with respect to change in BMD, although bone density may change differentially depending on site in males and females.^35,37 Alendronate increased the BMD at the lumbar spine and the hipbone in males (P < .05), but only at the lumbar spine in females (P < .05).³⁷ Male gender was also associated with a greater improvement in lumbar spine BMD in patients receiving osteoporosis treatment (P < .01).³⁵

Diabetes

Three studies^32,37,39 examined the role of diabetes in bone loss, but none investigated the duration or control of diabetes pretransplantation. One study³² identified pretransplantation diabetes as an independent risk factor for low BMD (P < .001), while the other 2 found a greater reduction in T-score at the lumbar spine in nondiabetic recipients (−0.52 ± 0.67 vs −0.15 ± 0.50, P < .01).³⁹ Consequently, diabetes was not a significant predictive factor in BMD (OR = 0.6).³⁷

Hemodialysis (HD) pretransplant

Only one study examined the impact of pretransplant HD duration on BMD.³⁹ The mean change reduction in T-score at the lumbar spine in the first year posttransplant was significantly greater in recipients who had been on HD for ≥12 months compared with those who had experienced dialysis <12 months (−0.67 ± 0.79 vs −0.39 ± 0.57, P = .001).³⁹

Smoking

In a multivariate analysis,³⁷ smoking was not a risk factor of BMD change posttransplantation (see Supplemental Table S2).

Discussion

This systematic review and meta-analysis is the first to investigate the bisphosphonate effects on increasing BMD and fracture prevention beyond the first year postkidney transplantation. A recently published meta-analysis by Wang et al²⁵ demonstrated that bisphosphonate treatment in general had a beneficial effect on BMD changes at both the lumbar spine and femoral neck, which is congruent with previous studies and established practice guidelines.⁴⁸ Although prior studies have shown that the most rapid decrease in lumbar spine BMD occurs within the first year posttransplantation (estimated at 3%-7%), we recognize declining BMD to be a problem of longer chronicity, often confounded by several factors unique to the immediate posttransplant period.^8-11,25

In our study, we demonstrate no statistically significant benefit of bisphosphonate treatment on BMD beyond the first year posttransplant. There was heterogeneity in studies’ treatment choice and duration, but a nonsignificant improvement in lumbar spine BMD was consistently seen, while the effect appeared inconsistent in the femoral neck. Two studies^28,39 captured peri-transplant patients’ data providing a baseline comparison, and both groups showed significant improvement with bisphosphonate treatment at the lumbar spine and femoral neck beyond 1 year posttransplant, when treatment was initiated at the time of transplantation and lasted for at least 1 year. This significant improvement persisted into the second^28,39 and third year³⁹ at the lumbar spine but not at the femoral neck.

As bone loss progresses beyond the first year posttransplantation,^9,12 we also analyzed the effects of bisphosphonates on BMD at least 12 months posttreatment initiation, regardless of the time from initial transplantation. Although bisphosphonate protocols varied widely across studies, 11 studies^{26-28,31,33,34,36,37,39-41} identified a significant increase in BMD at 12 months posttreatment as compared with baseline.

This review demonstrated no statistically significant change in BMD beyond 1 year with bisphosphonates. Thus, the benefit of bisphosphonates may be only evident within 1 year of transplant. This is an important observation, as the protective effect may be limited to the time with highest corticosteroid dosing, and other pre- and posttransplant factors such as inflammation or bone disease. This likely indicated that there is no benefit to bisphosphonate use in renal transplant recipients beyond 1 year posttransplantation.

Despite the significant changes found with the bisphosphonate treatment at the lumbar vertebral levels, only 3 studies^31,33,39 displayed improvement at the femoral neck level. Although this does not translate directly to a lower fracture risk, this may extrapolate into ongoing hip fracture risks with greater protective effect at the lumbar spines in this population. This is a clinical consideration when risk-stratifying patients based on their BMD and fracture risks posttransplant. A significant limitation is that none of the studies captured fracture incidence as the sole primary outcome, likely given the paucity of fracture events.

Only one study³⁸ was able to interpret fracture results beyond reporting incidence and found no difference (HR = 0.40; 95% CI = 0.29-0.73, P = .001) in fracture rate after bisphosphonate treatment in their adjusted analysis.³⁸ Thus, the clinical significance of bisphosphonate therapy on patient morbidity with fracture prevention remains to be established.

Steroid use in both the early and long-term posttransplant periods has been shown to cause increased bone loss.³⁷ Specifically, prednisone doses of >7.5 mg/d results in trabecular bone loss in most patients.⁴¹ Calcineurin inhibitors have also been implicated in bone loss in animal models.³⁷ While all studies that examined steroid use reaffirmed their deleterious impact on bone health, the effect of bisphosphonates in patient populations that had received higher cumulative steroid doses was not congruent. Only Huang et al³⁷ was able to demonstrate that bisphosphonates resulted in a greater improvement in BMD at the lumbar spine in those with osteoporosis at baseline versus osteopenic patients.

Previous systematic reviews on a similar population highlighted limitations of few studies and small sample sizes. Thus, the wide scope of literature analyzed in this study sought to address this by including both observational and randomized control trials with appropriate bias analysis. A second strength of this study is our focus on long-term effectiveness of bisphosphonate treatment. It is important to recognize that the predominant population to which these data apply is well beyond the initial 12-month posttransplant and that these are the patients who carry the burden of bone disease. Our findings on bisphosphonate treatment in BMD preservation beyond 12 months posttransplant highlight limited evidence supporting the use of bisphosphonates on renal osteodystrophy.

Limitations of this review include the use of BMD as a surrogate outcome, the bias of the included studies, and the incomplete reporting data in numerous analyzed studies. The most clinically relevant outcome is the incidence of fractures. Our review assessed BMD as the primary outcome, acknowledging that BMD is not an accurate indicator of clinically meaningful patient outcomes and quality of life. Other indicators, such as bone biopsy, should be considered as a surrogate outcome in the future, keeping in mind that biopsy is expensive, invasive, and biopsy-based treatment guidelines are not yet available. We had limited information on the bone turnover state of patients to identify patients who would potentially benefit from anti-resorptive therapy. Last, we recognize that high risk of bias was identified in 44% of our included studies. We elected to include these studies given the limited sample size of the renal transplant population. The conclusions drawn from this review, however, did not change based on this bias assessment.

In conclusion, our review finds no statistical evidence for improvement in BMD in renal transplant patients beyond the first year posttransplantation with the use of bisphosphonates. We detected a differential improvement in BMD favoring the lumbar spine more so than the femoral neck, which may have clinical implications despite nonsignificance. However, the limitations of this review highlight the need for randomized control trials in patients with quantified bone turnover status evaluating fracture risk. Also quantifying other surrogate outcomes such as bone biopsy is necessary to provide more definitive evidence for the use of bisphosphates for current practice guidelines. In our future work, we plan to explore the evidence on the safety profile of bisphosphonates in this unique population with a focus on graft function. Finally, anti-resorptive and anabolic therapies are alternatives to bisphosphonates in bone mineral diseases in the general population and investigation into the use of these therapies in the renal transplant population is an avenue to further treatment options.

Supplemental Material

updated_supplementary_file – Supplemental material for Effect of Bisphosphonates on Bone Health in Adult Renal Transplant Patients: Beyond the First Year Posttransplant—A Systematic Review and Meta-Analysis

Supplemental material, updated_supplementary_file for Effect of Bisphosphonates on Bone Health in Adult Renal Transplant Patients: Beyond the First Year Posttransplant—A Systematic Review and Meta-Analysis by Alyssa Lip, Ashley Warias, M. Khaled Shamseddin, Benjamin Thomson and D. Thiwanka Wijeratne in Canadian Journal of Kidney Health and Disease

Footnotes

List of Abbreviations

AMTD, adjusted mean treatment difference; BMD, bone mineral density; BMI, body mass index; CI, confidence interval; CKD, chronic kidney disease; DEXA, dual energy X-ray absorptiometry; ESRD, end-stage renal disease; MBD, mineral and bone disorders; RCT, randomized control trial; SD, standard deviation.

Ethics Approval and Consent to Participate

No ethics was required as our study reviewed existing literature.

Consent for Publication

AL and AW independent screened and reviewed all articles. AL and AW are the primary authors of this manuscript. MKS, BT, and DTW provided supervision and clinical expertise. All authors have consented for publication.

Availability of Data and Materials

All data is provided in the article and supplementary tables. Primary data can be obtained directly from the original articles.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iDs

Alyssa Lip

Benjamin Thomson

Supplemental Material

Supplemental material for this article is available online.

References

Coco

Glicklich

Faugere

, et al. Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol. 2003;14(10):2669-2676.

Ziegler

Kasperk

Glucocorticoid-induced osteoporosis: prevention and treatment. Steroids. 1998;63(5-6):344-348.

Sherrard

Hercz

Pei

, et al. The spectrum of bone disease in end-stage renal failure: an evolving disorder. Kidney Int. 1993;43(2):436-442.

Malluche

Faugere

Renal bone disease 1990: an unmet challenge for the nephrologist. Kidney Int. 1990;38:193-211.

Kalantar-Zadeh

Molnar

Kovesdy

Mucsi

Bunnapradist

Management of mineral and bone disorder after kidney transplantation. Curr Opin Nephrol Hypertens. 2012;21(4):389-403.

Nishimura

Ikuyama

Glucocorticoid-induced osteoporosis: pathogenesis and management. J Bone Miner Metab. 2000;18(6):350-352.

Grotz

Nagel

Poeschel

, et al. Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol. 2001;12(7):1530-1537.

Rodino

Shane

Osteoporosis after organ transplantation. Am J Med. 1998;104(5):459-469.

Julian

Laskow

Dubovsky

Curtis

Quarles

LD.

Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med. 1991;325(8):544-550.

10.

Horber

Casez

Steiger

Czerniak

Montandon

Jaeger

Changes in bone mass early after kidney transplantation. J Bone Miner Res. 1994;9(1):1-9.

11.

Kwan

Almond

Evans

Cunningham

Changes in total body bone mineral content and regional bone mineral density in renal patients following renal transplantation. Miner Electrolyte Metab. 1992;18(2-5):166-168.

12.

Pichette

Bonnardeaux

Prudhomme

Gagné

Cardinal

Ouimet

Long-term bone loss in kidney transplant recipients: a cross-sectional and longitudinal study. Am J Kidney Dis. 1996;28(1):105-114.

13.

Akaberi

Simonsen

Lindergård

Nyberg

Can DXA predict fractures in renal transplant patients. Am J Transplant. 2008;8(12):2647-2651.

14.

Omidvar

Ghorbani

Shahbazian

Beladi Mousavi

Shariat Nabavi

Alasti

Comparison of alendronate and pamidronate on bone loss in kidney transplant patients for the first 6 months of transplantation. Iran J Kidney Dis. 2011;5(6):420-424.

15.

Cohen

Shane

Osteoporosis after solid organ and bone marrow transplantation. Osteoporos Int. 2003;14(8):617-630.

16.

Casez

Lippuner

Horber

Montandon

Jaeger

Changes in bone mineral density over 18 months following kidney transplantation: the respective roles of prednisone and parathyroid hormone. Nephrol Dial Transplant. 2002;17(7):1318-1326.

17.

Nouri-Majalan

Sanadgol

Rahimian

Soleimani

Bone mineral density in kidney transplant recipients and patients on hemodialysis: a comparison with healthy individuals. Iran J Kidney Dis. 2008;2(3):154-159.

18.

Palmer

Strippoli

McGregor

DO.

Interventions for preventing bone disease in kidney transplant recipients: a systematic review of randomized controlled trials. Am J Kidney Dis. 2005;45(4):638-649.

19.

Fan

Almond

Ball

Evans

Cunningham

Pamidronate therapy as prevention of bone loss following renal transplantation. Kidney Int. 2000;57(2):684-690.

20.

El-Agroudy

El-Husseini

El-Sayed

Mohsen

Ghoneim

MA.

A prospective randomized study for prevention of postrenal transplantation bone loss. Kidney Int. 2005;67(5):2039-2045.

21.

Weber

Quarles

LD.

Preventing bone loss after renal transplantation with bisphosphonates: we can . . . but should we?

Kidney Int. 2000;57(2):735-737.

22.

ten Dam

Hilbrands

Wetzels

JF.

Nephrotic syndrome induced by pamidronate. Med Oncol. 2011;28(4):1196-1200.

23.

Wilson

Rebholz

Jirru

, et al. Benefits and harms of osteoporosis medications in patients with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2017;166(9):649-658.

24.

Kan

Ning

Chen

Zhou

Sun

Feng

SQ.

Efficacy and safety of bisphosphonates for low bone mineral density after kidney transplantation: a meta-analysis. Medicine (Baltimore). 2016;95(5):e2679.

25.

Wang

Yao

Shu

Wang

Cui

XJ.

Bisphosphonates for prevention of osteopenia in kidney-transplant recipients: a systematic review of randomized controlled trials. Osteoporos Int. 2016;27(5):1683-1690.

26.

Sánchez-Escuredo

Fuster

Rubello

, et al. Monthly ibandronate versus weekly risedronate treatment for low bone mineral density in stable renal transplant patients. Nucl Med Commun. 2015;36(8):815-818.

27.

Okamoto

Yamanaka

Yoshimoto

Shigematsu

. Alendronate as an effective treatment for bone loss and vascular calcification in kidney transplant recipients. J Transplant. 2014; 2014: 269613. doi: 10.1155/2014/269613

28.

Walsh

Altmann

Pattison

, et al. Effect of pamidronate on bone loss after kidney transplantation: a randomized trial. Am J Kidney Dis. 2009;53(5):856-865.

29.

Lan

Peng

Xie

Peng

Wang

Alendronate is effective to treat bone loss in renal transplantation recipients. Transplant Proc. 2008;40:3496-3498.

30.

Schwarz

Mitterbauer

Heinze

Woloszczuk

Haas

Oberbauer

Nonsustained effect of short-term bisphosphonate therapy on bone turnover three years after renal transplantation. Kidney Int. 2004;65(1):304-309.

31.

Fan

Kumar

Cunningham

Long-term effects on bone mineral density of pamidronate given at the time of renal transplantation. Kidney Int. 2003;63(6):2275-2279.

32.

Jeffery

Leslie

Karpinski

Nickerson

Rush

DN.

Prevalence and treatment of decreased bone density in renal transplant recipients: a randomized prospective trial of calcitriol versus alendronate. Transplantation. 2003;76(10):1498-1502.

33.

Koc

Tuglular

Arikan

Ozener

Akoglu

Alendronate increases bone mineral density in long-term renal transplant recipients. Transplant Proc. 2002;34:2111-2113.

34.

Tillmann

Schmitz

Jager

Krauspe

Rump

LC.

Ibandronate in stable renal transplant recipients with low bone mineral density on long-term follow-up. Int Urol Nephrol. 2016;48(2):279-286.

35.

Naylor

Garg

Hodsman

Rush

Leslie

WD.

Long-term changes in bone mineral density in kidney transplant recipients. Transplantation. 2014;98(12):1279-1285.

36.

Yamamoto

Suzuki

Sasaki

, et al. Oral alendronate can suppress bone turnover but not fracture in kidney transplantation recipients with hyperparathyroidism and chronic kidney disease. J Bone Miner Metab. 2013;31(1):116-122.

37.

Huang

Lee

Weng

Lai

PC.

Use of alendronate sodium (Fosamax) to ameliorate osteoporosis in renal transplant patients: a case-control study. PLoS ONE. 2012;7(11):e48481.

38.

Conley

Muth

Samaniego

, et al. Bisphosphonates and bone fractures in long-term kidney transplant recipients. Transplantation. 2008;86(2):231-237.

39.

Ahn

Kim

, et al. Risk factors for changes in bone mineral density and the effect of antiosteoporosis management after renal transplantation. Transplant Proc. 2006;38:2074-2076.

40.

Cruz

Brickel

Wysolmerski

, et al. Treatment of osteoporosis and osteopenia in long-term renal transplant patients with alendronate. Am J Transplant. 2002;2(1):62-67.

41.

Arlen

Lambert

Ioannidis

Adachi

JD.

Treatment of established bone loss after renal transplantation with etidronate1. Transplantation. 2001;71(5):669-673.

42.

Genant

van Kuijk

Nevitt

MC.

Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993;8(9):1137-1148.

43.

Higgins

Altman

Gøtzsche

, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.

44.

Wells

, et al. Newcastle-Ottawa Quality Assessment Scale Cohort Studies. Ontario, Canada: University of Ottawa; 2014.

45.

Lipsey

Wilson

DB.

Practical Meta-Analysis. Thousand Oaks, CA: Sage; 2001.

46.

Higgins

Green

. Cochrane Handbook for Systematic Reviews of Interventions. Vol. 4. West Sussex, England: John Wiley; 2011.

47.

Wei

Jackson

Hatzigeorgiou

Tofferi

JK.

Osteoporosis management in the new millennium. Prim Care. 2003;30(4):711-741.

48.

EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: long-term management of the transplant recipient. IV. 8. Bone disease. Nephrol Dial Transplant. 2002;17:43.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.81 MB

1.14 MB